Charles Schwab Investment Management Inc Curis Inc Transaction History

Charles Schwab Investment Management Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.74 - $15.01 $42,246 - $856,920	57,090 New	57,090 $40,000
Q2 2022 Aug 15, 2022	SELL	$0.71 - $2.43 $160,290 - $548,599	-225,761 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$2.31 - $5.13 $18,352 - $40,757	7,945 Added 3.65%	225,761 $538,000
Q4 2021 Feb 11, 2022	BUY	$4.45 - $8.09 $18,743 - $34,075	4,212 Added 1.97%	217,816 $1.04 Million
Q3 2021 Nov 16, 2021	BUY	$6.94 - $8.85 $16,433 - $20,956	2,368 Added 1.12%	213,604 $1.67 Million
Q2 2021 Aug 16, 2021	BUY	$7.45 - $16.27 $1.37 Million - $2.99 Million	183,623 Added 664.99%	211,236 $1.71 Million
Q1 2021 May 17, 2021	BUY	$8.78 - $12.8 $72,514 - $105,715	8,259 Added 42.67%	27,613 $313,000
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $20,902 - $158,702	19,354 New	19,354 $159,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.